SAS Output

25-APR-2019 6:11

OPEN STUDIES IRB REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Disease
Site
Study Study Name Open Date Number of
Active
Institutions
Number of
Current
IRBs
 
BREAST S1207 Brst,Adj,Endocrine+/-Everolimus 03-SEP-13 427 198
  S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 07-JUL-16 256 114
  S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 15-NOV-16 474 206
  S1706 Breast, Inflammatory, RT +/- Olaparib 12-SEP-18 0 58
  A011106 Breast, Neoadj, ALTERNATE study 15-FEB-14 271 112
  A011401 Breast, adj, Stage II/III HER2-, weight loss 29-AUG-16 477 246
  A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo 08-DEC-16 0 205
  A221405 Breast, ET interruption, Pregnancy Outcomes 15-OCT-15 0 51
  B51 Breast, Regional Nodal XRT 22-AUG-13 285 159
  B55 Brst, Adj Olaparib for BRCA,TNBC 03-JUL-14 439 184
  E1Z11 Brst,Genetic Predictors of AIMSS 10-MAY-13 0 1
  EA1131 Brst, TNBC, Post-op Chemo vs Obs 20-AUG-14 255 120
  EA1151 Brst, Tomosynthesis Mammographic Screening 06-JUL-17 0 71
  NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA 24-DEC-14 0 143
  NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo 22-JAN-15 316 168
  NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv 13-APR-17 0 78
 
CCD S1703 Met Breast, STM-monitoring v Usual Care 16-JUL-18 0 70
  A191402C PROS, Testing Decision Aids for Minority Men 14-JUL-17 0 9
  ACCL16N1 Guideline Consistent Treatment AYA ALL 18-DEC-17 0 48
  EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer 17-MAY-18 0 67
 
ERLYTX S1609 Rare Tumor, Comb Nivo/Ipi 13-JAN-17 315 156
  A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib 06-AUG-15 229 90
  ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) 16-MAY-14 243 120
  EAY131 MATCH 12-AUG-15 378 208
 
GI S1613 mCRC, Adv/Met, TP vs CETIRI 09-OCT-17 0 113
  S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel 03-DEC-18 0 71
  A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT 01-DEC-16 0 1
  A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC 12-SEP-17 0 161
  EA2142 GI NEC, Adv G3, EP vs TMZ + CAP 06-NOV-15 189 78
  EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 01-FEB-17 0 11
  EA2165 Anal, Stg II-III, Nivolumab after CMT 13-APR-18 0 45
  NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy 07-NOV-17 0 118
 
GU S1500 pRCC,Adv, Sunitinib vs MET inhib 05-APR-16 212 87
  S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 07-FEB-17 173 70
  S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab 07-FEB-17 196 91
  S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum 17-SEP-18 0 90
  A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) 01-JUL-15 62 40
  A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs 21-SEP-17 0 125
  A031701 Bladder, ddGC for MIBC with DDR Tumor Alt 01-AUG-18 0 4
  EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) 02-FEB-17 0 146
  EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) 08-FEB-18 0 27
  EA8171 PROS, newly diagnosed, mpMRI for pre-op stagi 09-JUL-18 0 29
  NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel 30-DEC-16 0 104
  NRGGU005 PROS, intmd risk, IGRT& SBRT vs IGRT& HF-IMRT 16-NOV-17 0 3
  R0924 Pros, NADT+WPRT vs. NADT+P&SV RT 07-JUL-11 0 115
 
LEUK S1712 CML, Chronic Phase, TKI +/- Ruxolitinib 20-JUL-18 0 60
  A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 01-JUN-17 0 56
  E1910 BCR-ABL-neg, B ALL, Blinatumomab 23-DEC-13 172 84
  E2906 AML, Age 60+, Clo vs Dauno+Cy 24-FEB-11 90 40
  EA9161 CLL, untreated, IOV vs IO in younger pts 03-JAN-19 0 55
  NHLBIMDS LEUK, National MDS Study 05-APR-16 209 80
 
LUNG S1400F Non-Match: MEDI4736 + Tremelimumab 02-OCT-17 0 205
  S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 03-NOV-17 0 28
  S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac 09-AUG-18 0 31
  S1900A LOH and/or BRCA: Rucaparib 28-JAN-19 0 68
  A081105 ALCHEMIST1, EGFR mut, Erlotinib 02-JAN-14 0 251
  A151216 ALCHEMIST0 - screening 06-FEB-14 485 251
  C30610 SCLC, Thoracic RT 21-MAR-08 155 85
  E4512 ALCHEMIST2, ALK mut, Crizotinib 18-AUG-14 375 215
  EA5142 ALCHEMIST3, Non-match, Nivolumab 16-MAY-16 459 246
  LUNGMAP NSCLC, Adv, Master 28-JAN-19 0 129
  NRGCC003 SCLC, PCI or HA-PCI 07-DEC-15 236 121
 
LYMPH S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob 10-AUG-17 0 116
  A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo 15-JUL-16 160 66
  EA4151 Lymph, AHCT +/-Ritux, MRD Neg 29-AUG-17 0 58
 
MELAN S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) 20-OCT-16 90 41
  S1607 MELAN, Adv, T-VEC, MK-3475 02-OCT-17 0 26
  S1616 MELAN, Adv, Ipilimumab ± Nivolumab 17-JUL-17 0 87
  S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab 06-DEC-18 0 77
  EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 15-DEC-15 360 143
  EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim 01-MAR-16 219 93
 
MMYEL S1702 AL Amyloidosis, Relapsed, Isatuximab 08-MAR-18 0 60
  E1A11 MM, frontline, BLD vs CLD 22-NOV-13 296 123
 
OTHER A091401 Sarc, 18-JUN-15 180 71
  EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp 29-MAR-16 0 68
  EAF151 Brain, GBM, Bev, Blood Volume 14-APR-17 0 36
  EAQ152 Communication & education in tumor profiling 26-SEP-16 184 78
  G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT 12-APR-10 0 62
  N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC 22-SEP-09 166 75
  NRGBN001 HN, novel vs. std chemoradiation + chemo 28-AUG-15 0 73
  NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care 06-FEB-16 329 142
  NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev 12-MAY-17 0 127
  NRGHN001 Nasopharyngeal , Indiviual Tx EBV 21-APR-14 146 65
  R0724 Cervical, Chem+RT +/- Adj. Chemo 15-JAN-14 193 79
  R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux 18-MAR-13 204 84
 
PREV S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac 01-MAR-13 0 2
 
SURV S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol 15-SEP-17 0 91
  E1Q11 EROS: Reproductive Health in Cancer Survivors 30-SEP-15 0 42
  EA9131 Leuk, Strategy to decrease early APL deaths 16-AUG-17 0 25
 
SXQOL S1600 Bladder,Radical Cystectomy Outcomes Nutrition 21-FEB-19 0 11
  S1614 HBV in Ca Pts, TAF vs SOC 21-FEB-19 0 15
  S1714 CIPN Risk Prediction Cohort Study, Taxanes 01-MAR-19 0 22
  A221101 Glioma, Nuvigil/Placebo Fatigue 03-JUN-13 9 2
  A221504 NSCL, Advanced, placebo vs naloxegol 13-OCT-17 0 71
  A221505 Brst, Hypofractionated Post Mast Rad 01-FEB-18 0 98